Catalina Capital Group LLC Acquires Shares of 48,964 Compass Therapeutics, Inc. (NASDAQ:CMPX)

Catalina Capital Group LLC bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 48,964 shares of the company’s stock, valued at approximately $71,000.

Several other large investors have also made changes to their positions in CMPX. Rovin Capital UT ADV bought a new stake in Compass Therapeutics during the 3rd quarter worth about $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the third quarter worth approximately $37,000. Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics in the second quarter valued at approximately $41,000. Finally, SG Americas Securities LLC boosted its stake in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Stock Up 1.3 %

Shares of NASDAQ:CMPX opened at $3.12 on Wednesday. The firm has a market cap of $429.28 million, a price-to-earnings ratio of -8.43 and a beta of 1.15. Compass Therapeutics, Inc. has a 12 month low of $0.76 and a 12 month high of $3.63. The company’s fifty day simple moving average is $1.96 and its 200 day simple moving average is $1.67.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Research analysts expect that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on CMPX shares. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. D. Boral Capital reissued a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.80.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.